Infographic: 3 Barriers to Biosimilar Uptake for Chronic Diseases

June 18, 2017
The Center for Biosimilars Staff

A viewpoint published in JAMA explains why biosimilar drugs approved in the United States for the treatment of chronic diseases may not result in expected cost savings.

A viewpoint published in JAMA explains why biosimilar drugs approved in the United States for the treatment of chronic diseases may not result in expected cost savings. Read more about the viewpoint here.

Related Content:

News | Business

x